IL213246A - Processes and intermediates for the preparation of HCV macrocyclic protease inhibitor - Google Patents

Processes and intermediates for the preparation of HCV macrocyclic protease inhibitor

Info

Publication number
IL213246A
IL213246A IL213246A IL21324611A IL213246A IL 213246 A IL213246 A IL 213246A IL 213246 A IL213246 A IL 213246A IL 21324611 A IL21324611 A IL 21324611A IL 213246 A IL213246 A IL 213246A
Authority
IL
Israel
Prior art keywords
hcv
intermediates
preparing
processes
protease inhibitor
Prior art date
Application number
IL213246A
Other languages
English (en)
Hebrew (he)
Other versions
IL213246A0 (en
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of IL213246A0 publication Critical patent/IL213246A0/en
Publication of IL213246A publication Critical patent/IL213246A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/475—Preparation of carboxylic acid esters by splitting of carbon-to-carbon bonds and redistribution, e.g. disproportionation or migration of groups between different molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL213246A 2008-12-23 2011-05-31 Processes and intermediates for the preparation of HCV macrocyclic protease inhibitor IL213246A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08172691 2008-12-23
PCT/EP2009/067715 WO2010072742A1 (en) 2008-12-23 2009-12-22 Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv

Publications (2)

Publication Number Publication Date
IL213246A0 IL213246A0 (en) 2011-07-31
IL213246A true IL213246A (en) 2017-10-31

Family

ID=40548041

Family Applications (1)

Application Number Title Priority Date Filing Date
IL213246A IL213246A (en) 2008-12-23 2011-05-31 Processes and intermediates for the preparation of HCV macrocyclic protease inhibitor

Country Status (22)

Country Link
US (2) US8927722B2 (https=)
EP (1) EP2382198B1 (https=)
JP (1) JP5687631B2 (https=)
KR (1) KR101734507B1 (https=)
CN (1) CN102264715B (https=)
AR (1) AR074863A1 (https=)
AU (1) AU2009331530B2 (https=)
BR (1) BRPI0923393B1 (https=)
CA (1) CA2745565C (https=)
CY (1) CY1114488T1 (https=)
DK (1) DK2382198T3 (https=)
ES (1) ES2429013T3 (https=)
HR (1) HRP20130906T1 (https=)
IL (1) IL213246A (https=)
MX (1) MX2011006764A (https=)
PL (1) PL2382198T3 (https=)
PT (1) PT2382198E (https=)
RU (1) RU2016120007A (https=)
SI (1) SI2382198T1 (https=)
SM (1) SMT201300116B (https=)
TW (1) TWI461424B (https=)
WO (1) WO2010072742A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5687631B2 (ja) 2008-12-23 2015-03-18 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｃｖのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体
CA2845720A1 (en) 2011-09-22 2013-03-28 Janssen Pharmaceuticals, Inc. Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
TWI574960B (zh) * 2011-10-28 2017-03-21 健生醫藥公司 用於製備大環蛋白酶抑制劑ｔｍｃ４３５之中間體的改良方法
CN103387509B (zh) * 2012-05-11 2016-06-08 重庆博腾制药科技股份有限公司 一种hcv蛋白酶抑制剂中间体的制备方法
EA026235B1 (ru) * 2012-06-08 2017-03-31 Джилид Сайэнс, Инк. Макроциклические ингибиторы вирусов flaviviridae
PT2859009T (pt) 2012-06-08 2018-01-18 Gilead Sciences Inc Inibidores macrocíclicos dos vírus flaviviridae
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US9617310B2 (en) 2013-03-15 2017-04-11 Gilead Sciences, Inc. Inhibitors of hepatitis C virus
CN105308043B (zh) * 2014-05-29 2018-01-30 杭州普晒医药科技有限公司 丙型肝炎药物的晶型及其制备方法、其药物组合物和用途
MA41812A (fr) 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8300536A (nl) 1983-02-14 1984-09-03 Oce Andeno Bv Optisch actief alfa-azido-p-hydroxyfenylazijnzuur en zijn zouten alsmede de bereiding daarvan.
JPS6124539A (ja) 1984-07-11 1986-02-03 Sagami Chem Res Center 光学活性（ｒ）−２，５，１２−トリヒドロキシ−１，２，３，４−テトラヒドロナフタセン−６，１１−ジオン−２−カルボン酸の取得方法
JP4218040B2 (ja) 1997-12-26 2009-02-04 曽田香料株式会社 有機酸とアミンの複合塩の製造法
JP3844112B2 (ja) 2000-08-23 2006-11-08 高砂香料工業株式会社 ３，５，６−トリヒドロキシヘキサン酸アンモニウム塩誘導体、及びその製造方法
PL1713822T3 (pl) 2004-01-30 2010-08-31 Medivir Ab Inhibitory proteazy serynowej HCV NS-3
CN101146794A (zh) * 2005-01-21 2008-03-19 阿斯泰克斯治疗有限公司 用于抑制cdk和gsk的吡唑衍生物
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US8012939B2 (en) * 2005-07-29 2011-09-06 Tibotec Pharmaceuticals Ltd. Co Macrocyclic inhibitors of hepatitis C virus
DE602008001251D1 (de) * 2007-02-01 2010-06-24 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
BRPI0807482A2 (pt) * 2007-02-08 2014-05-13 Tibotec Pharm Ltd Fenilcarbamatos macrocíclicos inibidores de hcv
JP5687631B2 (ja) 2008-12-23 2015-03-18 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツドＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｈｃｖのマクロ環状プロテアーゼ阻害剤を製造するための方法および中間体

Also Published As

Publication number Publication date
BRPI0923393A2 (pt) 2015-07-28
JP5687631B2 (ja) 2015-03-18
TWI461424B (zh) 2014-11-21
AU2009331530B2 (en) 2015-04-09
AU2009331530A1 (en) 2011-06-23
CA2745565A1 (en) 2010-07-01
SI2382198T1 (sl) 2013-11-29
CA2745565C (en) 2017-03-07
KR20110099048A (ko) 2011-09-05
AR074863A1 (es) 2011-02-16
CN102264715A (zh) 2011-11-30
KR101734507B1 (ko) 2017-05-11
JP2012513381A (ja) 2012-06-14
US20150080577A1 (en) 2015-03-19
PL2382198T3 (pl) 2013-11-29
MX2011006764A (es) 2011-08-03
ES2429013T3 (es) 2013-11-12
EP2382198A1 (en) 2011-11-02
WO2010072742A1 (en) 2010-07-01
US8927722B2 (en) 2015-01-06
EP2382198B1 (en) 2013-07-10
BRPI0923393B1 (pt) 2018-06-19
CY1114488T1 (el) 2016-10-05
CN102264715B (zh) 2015-12-02
HRP20130906T1 (hr) 2013-10-25
PT2382198E (pt) 2013-10-01
HK1164839A1 (zh) 2012-09-28
RU2011130895A (ru) 2013-01-27
SMT201300116B (it) 2013-11-08
US9115077B2 (en) 2015-08-25
US20110257403A1 (en) 2011-10-20
DK2382198T3 (da) 2013-09-30
RU2016120007A (ru) 2018-11-13
IL213246A0 (en) 2011-07-31
TW201033205A (en) 2010-09-16

Similar Documents

Publication Publication Date Title
PL2121674T3 (pl) Sposoby i związki pośrednie do wytwarzania makrocyklicznego inhibitora proteazy HCV
IL213246A0 (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
ZA200905377B (en) Polymorphic forms of a macrocyclic inhibitor of HCV
IL219123A0 (en) Combinations of a specific hcv ns5a inhibitor and an hcv ns3 protease inhibitor
ZA201202631B (en) Hcv protease inhibitors
HUS1500020I1 (hu) Makrociklusos Hepatitis C szerin proteáz inhibitorok
EP2398474A4 (en) HCV NS5A SHEMMER
ZA201008988B (en) Hcv protease inhibitors
IL225412A (en) Hcv serine protease inhibitors derived from macrocycle proline
EP2432318A4 (en) NS3 PROTEASE INHIBITORS OF BIPACROCYCLIC HEPATITIS C VIRUS
EP2364159A4 (en) DETERIORIC MACROCYCLIC INHIBITORS OF NS3 VIRAL PROTEASE
IL221242A0 (en) Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv
IL231024A0 (en) Processes and intermediates for the preparation of a macrocyclic protease inhibitor for hepatitis c virus
SG2014011258A (en) Hcv protease inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees